Avalyn Pharma Inc. (AVLN)
NASDAQ: AVLN · Real-Time Price · USD
29.76
-0.52 (-1.72%)
Nov 16, 2026, 4:00 PM EST - Market closed

Avalyn Pharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024
Period EndingSep '26 Dec '25 Dec '24
Operating Income
-117.77-91.29-55.72
Net Income
-109.39-85.2-49.74
Earnings Per Share
-5.69-87.74-184.14
EPS Growth
---

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024
Period EndingSep '26 Dec '25 Dec '24
Cash & Investments
386.6138.41118.12
Total Debt
16.931.67-
Net Cash (Debt)
369.67136.74118.12
Net Cash Growth
212.96%15.76%-
Net Cash Per Share
19.22140.82437.25

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024
Period EndingSep '26 Dec '25 Dec '24
Operating Cash Flow
-106.44-81.48-48.37
Capital Expenditures
-0.91-0.34-0.1
Free Cash Flow
-107.35-81.83-48.46
Free Cash Flow Growth
---